Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 429-441

  Li, Jia ^a   Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Advanced colon cancer; Angiogenesis; Bevacizumab; Chemotherapy; Gastric cancer; Hepatocellular cancer; Metastatic; Pancreatic cancer; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

EID: 77956497621     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S5874     Document Type: Review

References (84)

1. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438:937-945.
2. Werther K, Christensen IJ, Brünner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol. 2000;26:657-662.
3. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000;88:2239-2245.
4. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999;79:1553-1563.
5. Claudio PP, Russo G, Kumar CA, et al. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance. Clin Cancer Res. 2004;10:3509-3517.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
7. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235: 442-447.
8. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
9. Augustin HG. Translating angiogenesis research into the clinic: the challenges ahead. Br J Radiol. 2003;76:(1):S3-S10.
10. Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother. 2005;6:1701-1711.
11. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359-1364.
12. Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm. 2004;61(21 Suppl 5):S21-S26.
13. Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy. 2008;28(11 Pt 2):23S-30S.
14. Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7:53-64.
15. http://www.fda.gov/bbs/topics/NEWS/2004/NEW01027.html.
16. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01488.html.
17. http://www.fda.gov/cder/Offices/OODP/whatsnew/bevacizumab200802.html.
18. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology. 2005;69 Suppl 3:46-56.
19. Burris H 3rd, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist. 2008;13:289-298.
20. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
21. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
22. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084-2091.
23. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343:905-914.
24. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX or the recer sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
25. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Grouppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005;23:4866-4875.
26. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
27. Hurwitz H, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23: 3502-3508.
28. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23:3697-3705.
29. Kabbinavar FF, Hambleton J, Mass RD, et al. Combination analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3705-3712.
30. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
31. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in firstline treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25:4779-4786.
32. Fuchs CS, Marshall J, Barrueco J, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in firstline treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008;26:689-690.
33. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.
34. Hochster H, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE study. J Clin Oncol. 2008;26:3523-3529. Erratum in: J Clin Oncol. 2008;26:4697.
35. Hochster HS, Grothey A, Shpilsky A, et al. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOXtbevacizumab (BEV) in the CONcePT trial; 2008 Gastrointestinal Cancers Symposium. Abstract 280.
36. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25:1539-1544.
37. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
38. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25:4557-4561.
39. Hecht JR, Mitchell E, Chidiac T, et al. An updated analysis of the safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) //panitumumab (pmab) for firstline treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). [abstract] In: Program and abstracts of the 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008.
40. Hecht JR, Mitchell E, Chidiac T, et al. Interim results from PACCE: Irinotecan (iri)/bevacizumab (bev) //panitumumab as first-line treatment for metastatic colorectal cancer. [abstract] In: Proceedings and abstracts of the 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008.
41. Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol. 2008;19:734-738.
42. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360: 563-572.
43. Combination chemotherapy and bevacizumab with or without erlotinib in treating patients with metastatic colorectal cancer that cannot be removed by surgery. www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00265824.
44. Irinotecan and Cetuximab with or without bevacizumab in treating patients with metastatic colorectal cancer that progressed during f irst-line therapy. http://clinicaltrials.gov/ct2/show/ NCT00499369.
45. Meyerhardt JA, Stuart K, Fuchs CS, et al. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007;18:1185-1189.
46. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. 2008 ASCO annual meeting. J Clin Oncol. 2008;26(May 20 Suppl; abstr 4006).
47. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol. 2009;27:18s(suppl; abstr LBA4).
48. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
49. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
50. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
51. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040.
52. Kim GP, Oberg A, Kabat B, et al. NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. [abstract] J Clin Oncol. 2006; ASCO Annual Meeting Proceedings Part I. Vol 24, No. 185 (June 20 Suppl):4113.
53. Kim GP, Oberg AL, Foster NR, et al. Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. [abstract] J Clin Oncol. 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 185 (June 20 Suppl):4553.
54. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516.
55. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946-3952.
56. Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to singleagent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol. 2007;18:1652-1659.
57. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.
58. Astsaturov NJ, Meropol NJ, Alpaugh RK, et al. A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. [abstract] J Clin Oncol. 2007; ASCO Annual Meeting Proceedings. Part I. Vol. 25, No. 18S (June 20 Suppl):4556.
59. Kindler HL, Gangadhar T, Karrison T, et al. Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). [abstract] J Clin Oncol. 2008; ASCO Annual Meeting Proceedings:Abstract 4502.
60. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebocontrolled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol. 2007;25:18(Suppl): Abstract 4508.
61. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III Trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231-2237.
62. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13:565-569.
63. Longo R, Cacciamani F, Naso G, et al. Pancreatic cancer: From molecular signature to target therapy. Crit Rev Oncol Hematol. 2008;68:197-211.
64. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
65. Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int. 2009;29:284-290.
66. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992-2998.
67. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898-1903.
68. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008;13:120-125.
69. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27:843-850.
70. Kaseb AO, Iwasaki M, Javle M, et al. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2009;27(15 Suppl):Abstract 4522.
71. Ong LC, Song IC, Jin Y, et al. Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model. Mol Imaging Biol. 2009;11:334-342.
72. Antiangiogenic treatment of HCC with bevacizumab and Rad001. http://www.clinicaltrials.gov/ct2/show/NCT00775073.
73. Tai CJ, Chiou HY, Wu CH, Pan S, Liu JD. Rapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high-dose fluorouracil plus leucovorin. Onkologie. 2006;29:179-180.
74. Holen KD, Mahoney MR, LoConte NK, et al. Efficacy report of a multicenter phase II trial testing a biologic-only combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) study. J Clin Oncol. 2008;26(Meeting Abstracts):Abstract 4522.
75. Eroglu A, Demirci S, Ayyildiz A, et al. Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer. 1999;80:1630-1634.
76. Karayiannakis A, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients. Ann Surg. 2002;236:37-42.
77. Ninomiya S, Inomata M, Tajima M, et al. Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice. J Surg Res. 2009;154:196-202.
78. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:5201-5206.
79. Kelsen D, Jhawer M, Ilson D, et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial. J Clin Oncol. 2009;27(15 Suppl): Abstract 4512.
80. El-Rayes BF, Patel B, Zalupski M, et al. A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer. J Clin Oncol. 2009;27(15 Suppl):Abstract 4563.
81. Yao JC, Ng C, Hoff PM, et al. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol. 2005; ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Suppl):Abstract 4007.
82. Kunz PL, Kuo T, Kaiser HL, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results. J Clin Oncol. 2008; 26(May 20 Suppl):Abstract 15502.
83. Kulke MH, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006; ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl):Abstract 4044.
84. Arnold R, Müller H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol. 2009;27(15 Suppl):Abstract 4508.